Spruce Biosciences Stock Performance
| SPRB Stock | USD 0.39 0.01 2.63% |
The entity has a beta of 0.21, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Spruce Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Spruce Biosciences is expected to be smaller as well. At this point, Spruce Biosciences has a negative expected return of -0.45%. Please make sure to validate Spruce Biosciences' kurtosis, as well as the relationship between the day median price and period momentum indicator , to decide if Spruce Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Spruce Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Spruce Biosciences stock holds potential as Oppenheimer targets upcoming Phase 2b results | 12/02/2024 |
2 | Disposition of 128020 shares by Szwarcberg Javier B. of Spruce Biosciences at 0.537 subject to Rule 16b-3 | 12/10/2024 |
3 | Oppenheimer cuts Spruce Biosciences to perform | 12/11/2024 |
4 | Disposition of 111000 shares by Szwarcberg Javier B. of Spruce Biosciences subject to Rule 16b-3 | 12/16/2024 |
5 | Disposition of 32005 shares by Szwarcberg Javier B. of Spruce Biosciences at 0.3887 subject to Rule 16b-3 | 12/20/2024 |
6 | Spruce Biosciences Appoints Interim Chief Medical Officer - TipRanks | 12/27/2024 |
7 | Spruce Biosciences, Inc. Receives 3.90 Consensus Target Price from Brokerages | 12/31/2024 |
8 | Acquisition by Gharib Samir M. of 308000 shares of Spruce Biosciences subject to Rule 16b-3 | 01/17/2025 |
9 | NeoGenomics Tops Q4 Earnings Estimates | 02/18/2025 |
| Begin Period Cash Flow | 24.7 M |
Spruce |
Spruce Biosciences Relative Risk vs. Return Landscape
If you would invest 54.00 in Spruce Biosciences on December 3, 2024 and sell it today you would lose (15.00) from holding Spruce Biosciences or give up 27.78% of portfolio value over 90 days. Spruce Biosciences is currently does not generate positive expected returns and assumes 4.2266% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Spruce, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Spruce Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Spruce Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Spruce Biosciences, and traders can use it to determine the average amount a Spruce Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1059
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SPRB |
Estimated Market Risk
| 4.23 actual daily | 37 63% of assets are more volatile |
Expected Return
| -0.45 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Spruce Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Spruce Biosciences by adding Spruce Biosciences to a well-diversified portfolio.
Spruce Biosciences Fundamentals Growth
Spruce Stock prices reflect investors' perceptions of the future prospects and financial health of Spruce Biosciences, and Spruce Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Spruce Stock performance.
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (15.63) % | ||||
| Current Valuation | (40.99 M) | ||||
| Shares Outstanding | 41.3 M | ||||
| Price To Book | 0.31 X | ||||
| Price To Sales | 2.26 X | ||||
| Revenue | 10.09 M | ||||
| Gross Profit | (28.96 M) | ||||
| EBITDA | (47.37 M) | ||||
| Net Income | (47.92 M) | ||||
| Cash And Equivalents | 93.3 M | ||||
| Cash Per Share | 3.96 X | ||||
| Total Debt | 4.61 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 9.55 X | ||||
| Book Value Per Share | 1.25 X | ||||
| Cash Flow From Operations | (33.27 M) | ||||
| Earnings Per Share | (0.95) X | ||||
| Market Capitalization | 16.07 M | ||||
| Total Asset | 103.95 M | ||||
| Retained Earnings | (197.23 M) | ||||
| Working Capital | 77.72 M | ||||
About Spruce Biosciences Performance
By analyzing Spruce Biosciences' fundamental ratios, stakeholders can gain valuable insights into Spruce Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Spruce Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Spruce Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.41) | (0.44) | |
| Return On Capital Employed | (0.59) | (0.62) | |
| Return On Assets | (0.41) | (0.44) | |
| Return On Equity | (0.72) | (0.68) |
Things to note about Spruce Biosciences performance evaluation
Checking the ongoing alerts about Spruce Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Spruce Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Spruce Biosciences generated a negative expected return over the last 90 days | |
| Spruce Biosciences has some characteristics of a very speculative penny stock | |
| Spruce Biosciences has high historical volatility and very poor performance | |
| Spruce Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 10.09 M. Net Loss for the year was (47.92 M) with loss before overhead, payroll, taxes, and interest of (28.96 M). | |
| Spruce Biosciences currently holds about 93.3 M in cash with (33.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Spruce Biosciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from zacks.com: NeoGenomics Tops Q4 Earnings Estimates |
- Analyzing Spruce Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Spruce Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Spruce Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Spruce Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Spruce Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Spruce Biosciences' stock. These opinions can provide insight into Spruce Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Spruce Stock analysis
When running Spruce Biosciences' price analysis, check to measure Spruce Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spruce Biosciences is operating at the current time. Most of Spruce Biosciences' value examination focuses on studying past and present price action to predict the probability of Spruce Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spruce Biosciences' price. Additionally, you may evaluate how the addition of Spruce Biosciences to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |